As effectiveness of immunomodulatory strategies depends on the pre-existence of anti-tumor CD8+ T cells (65), we proposed that the risk score developed in this work can predict patients’ response to immune checkpoint blockade inhibitors (ICIs) due to its strong inverse correlation with CD8+ T cell infiltration and the tumor mutation burden. The gene discussed is CD8A; the disease is neoplasm.